Natalia Figueiredo1, Sunil K Srivastava2, Rishi P Singh3, Amy Babiuch2, Sumit Sharma3, Aleksandra Rachitskaya3, Katherine Talcott2, Jamie Reese2, Ming Hu4, Justis P Ehlers5. 1. The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 2. The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Vitreoretinal Service, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 3. Vitreoretinal Service, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 4. The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 5. The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Vitreoretinal Service, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: ehlersj@ccf.org.
Abstract
PURPOSE: To characterize the longitudinal panretinal retinal vascular dynamics in diabetic macular edema (DME) and retinal vein occlusion (RVO) over a 12-month period while being treated with intravitreal aflibercept injections (IAIs). DESIGN: Prospective open-label study (clinicaltrials.gov identifier, NCT02503540). PARTICIPANTS: Thirty-one treatment-naive eyes with foveal-involving retinal edema secondary to DME and RVO. METHODS: Participants received 2 mg IAI every 4 weeks for the first 6 months, followed by 2 mg every 8 weeks. Ultra-widefield fluorescein angiography (UWFA; California Optos [Optos, Dunfermline, United Kingdom]) and spectral-domain OCT (Cirrus; Zeiss, Oberkochen, Germany) scans were obtained and analyzed using a novel quantitative assessment platform. Visual acuity, central subfield thickness, and adverse events also were collected. MAIN OUTCOME MEASURES: The primary end point was the mean change in panretinal leakage index at month 12 from baseline as measured by UWFA. RESULTS:Mean age was 67.1 years. At month 12, visual acuity significantly improved by a mean of 18.4±21.4 letters (P < 0.0001), and central subfield thickness also improved significantly, with a mean reduction of 301.3±250.3 μm (P < 0.0001). Mean panretinal leakage index improved significantly, decreasing from 3.4% at baseline to 0.5% at month 6 (P <0.0001) and 0.4% at month 12 (P < 0.0001). Panretinal ischemic index did not demonstrate any significant change but showed a nonsignificant increase from 5.5% at baseline to 6.1% at month 6 (P = 0.315) and 8.7% at month 12 (P = 0.193). Eyes with DME showed a decrease in leakage index from 3.5±2.7% at baseline to 1.6±0.8% at month 12 (P = 0.018) and overall stability in ischemic index from 5.0±4.1% at baseline to 4.7±3.5% at month 12 (P = 0.689). Participants with RVO showed a decrease in leakage index from 3.3±1.1% at baseline to 0.02±0.03% at 12 months (P < 0.0001) and a nonsignificant increase in ischemic index from 5.9±4.5% at baseline to 12.6±9.8% at month 12 (P = 0.172). CONCLUSIONS:Intravitreal aflibercept injections resulted in a dramatic reduction in panretinal leakage index. Panretinal ischemic index did not improve and trended toward worsening.
RCT Entities:
PURPOSE: To characterize the longitudinal panretinal retinal vascular dynamics in diabetic macular edema (DME) and retinal vein occlusion (RVO) over a 12-month period while being treated with intravitreal aflibercept injections (IAIs). DESIGN: Prospective open-label study (clinicaltrials.gov identifier, NCT02503540). PARTICIPANTS: Thirty-one treatment-naive eyes with foveal-involving retinal edema secondary to DME and RVO. METHODS:Participants received 2 mg IAI every 4 weeks for the first 6 months, followed by 2 mg every 8 weeks. Ultra-widefield fluorescein angiography (UWFA; California Optos [Optos, Dunfermline, United Kingdom]) and spectral-domain OCT (Cirrus; Zeiss, Oberkochen, Germany) scans were obtained and analyzed using a novel quantitative assessment platform. Visual acuity, central subfield thickness, and adverse events also were collected. MAIN OUTCOME MEASURES: The primary end point was the mean change in panretinal leakage index at month 12 from baseline as measured by UWFA. RESULTS: Mean age was 67.1 years. At month 12, visual acuity significantly improved by a mean of 18.4±21.4 letters (P < 0.0001), and central subfield thickness also improved significantly, with a mean reduction of 301.3±250.3 μm (P < 0.0001). Mean panretinal leakage index improved significantly, decreasing from 3.4% at baseline to 0.5% at month 6 (P <0.0001) and 0.4% at month 12 (P < 0.0001). Panretinal ischemic index did not demonstrate any significant change but showed a nonsignificant increase from 5.5% at baseline to 6.1% at month 6 (P = 0.315) and 8.7% at month 12 (P = 0.193). Eyes with DME showed a decrease in leakage index from 3.5±2.7% at baseline to 1.6±0.8% at month 12 (P = 0.018) and overall stability in ischemic index from 5.0±4.1% at baseline to 4.7±3.5% at month 12 (P = 0.689). Participants with RVO showed a decrease in leakage index from 3.3±1.1% at baseline to 0.02±0.03% at 12 months (P < 0.0001) and a nonsignificant increase in ischemic index from 5.9±4.5% at baseline to 12.6±9.8% at month 12 (P = 0.172). CONCLUSIONS: Intravitreal aflibercept injections resulted in a dramatic reduction in panretinal leakage index. Panretinal ischemic index did not improve and trended toward worsening.
Authors: Wenying Fan; Kang Wang; Khalil Ghasemi Falavarjani; Min Sagong; Akihito Uji; Michael Ip; Charles C Wykoff; David M Brown; Jano van Hemert; SriniVas R Sadda Journal: Am J Ophthalmol Date: 2017-06-01 Impact factor: 5.258
Authors: David M Brown; Jeffrey S Heier; W Lloyd Clark; David S Boyer; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Rupert Sandbrink; Xiaoping Zhu; Julia A Haller Journal: Am J Ophthalmol Date: 2012-12-04 Impact factor: 5.258
Authors: Daniel E Croft; Jano van Hemert; Charles C Wykoff; David Clifton; Michael Verhoek; Alan Fleming; David M Brown Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2014 Jul-Aug Impact factor: 1.300
Authors: Dawn A Sim; Pearse A Keane; Ranjan Rajendram; Michael Karampelas; Senthil Selvam; Michael B Powner; Marcus Fruttiger; Adnan Tufail; Catherine A Egan Journal: Am J Ophthalmol Date: 2014-04-04 Impact factor: 5.258
Authors: Michael J Allingham; Dibyendu Mukherjee; Erin B Lally; Hossein Rabbani; Priyatham S Mettu; Scott W Cousins; Sina Farsiu Journal: Transl Vis Sci Technol Date: 2017-03-21 Impact factor: 3.283
Authors: Charles C Wykoff; Hannah J Yu; Robert L Avery; Justis P Ehlers; Ramin Tadayoni; SriniVas R Sadda Journal: Eye (Lond) Date: 2022-01-11 Impact factor: 3.775
Authors: Alice C Jiang; Duriye Damla Sevgi; Christopher Mugnaini; Jon Whitney; Sunil K Srivastava; Katherine E Talcott; Ming Hu; Jamie L Reese; Justis P Ehlers Journal: J Pers Med Date: 2022-04-10
Authors: Joseph R Abraham; Charles C Wykoff; Sruthi Arepalli; Leina Lunasco; Hannah J Yu; Alison Martin; Christopher Mugnaini; Ming Hu; Jamie Reese; Sunil K Srivastava; David M Brown; Justis P Ehlers Journal: Br J Ophthalmol Date: 2021-06-07 Impact factor: 5.908
Authors: Sudeshna Sil Kar; Duriye Damla Sevgi; Vincent Dong; Sunil K Srivastava; Anant Madabhushi; Justis P Ehlers Journal: IEEE J Transl Eng Health Med Date: 2021-07-12